Table 2.
Hazard ratios (95% confidence interval) for initial and recurrent heart failure hospitalization according to randomized groups and type 2 diabetes (T2D) status*
| Sequence of heart failure hospitalization |
Prevalent T2D at baseline |
No prevalent T2D at baseline |
P interaction T2D x omega-3 fatty acids |
||||
|---|---|---|---|---|---|---|---|
| Active Omega-3 Events/Total |
Omega-3 placebo Events/Tota1 |
Hazard Ratio (95% CI) p-value |
Active Omega-3 Events/Total |
Omega-3 placebo Events/Tota1 |
Hazard Ratio (95% CI) p-value |
||
| Initial | 65/1,784 | 90/1,738 | 0.69 (0.50-0.95) | 177/11,053 | 164/11,163 | 1.09 (0.88-1.34) | 0.019 |
| Recurrent ƚ | 88/1,879 | 158/1,904 | 0.53 (0.41-0.69) | 240/11,357 | 226/11,395 | 1.07 (0.89-1.28) | <0.0001 |
*
All models adjusted for age, sex, and vitamin D assignment versus placebo
ƚ
Hnclusive of 36 participants with prevalent heart failure at randomization